CTLA4 and neoplasm: Moreover, when we combined Nivolumab with the novel anti-CTLA-4 ID1 mAb, we observed an enhanced effect on LDH release raising up to 50 and 60%, respectively on MDA-MB-231 and BT-549 tumor cell lines (Figure 4A and Figure 5A), respectively, thus indicating the higher efficiency of this combination, compared to the lower effect (about 30%) observed when Nivolumab was combined with Ipilimumab.